360head Stockiq
Global Intelligence Terminal
Loading live prices…
LIVE
--:--:--
AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results. Always do your own research.

Alnylam Pharmaceuticals Inc (ALNY)

Price $165.04 · +5.36% today · $22.1B market cap.

biotech_pharma
Strongest Overalllow risk← Back
Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.
Price & Performance
$165.04 -25.3% over 1Y
Simulated history — illustrative, not real market data.
Today
+5.36%
1 week
+5.38%
1 month
+0.02%
1 year
-63.65%
Technical Analysis
RSI (14)
42.90
MACD
-1.18
MACD signal
-0.48
MACD hist
-0.69
SMA 20
171.88
SMA 50
173.29
EMA 20
171.62
ATR (14)
5.95
Support
163.71
Resistance
181.51
Bollinger upper
180.41
Bollinger lower
163.36

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis
P/E ratio
8.11
Return on equity
160%
EBITDA
n/a
EPS (TTM)
19.75
Net debt
n/a
Net margin
54.34%
Gross margin
77.28%
Current ratio
2.48
Debt / Equity
0.76
Dividend yield
n/a
Operating margin
19.43%
Revenue growth (YoY)
56.17%
Risk Assessment
Ann. volatility
46.1%
Max drawdown
47.1%
Liquidity
Adequate market capitalization
Leverage
Debt/equity 0.8 (manageable)
Valuation
P/E 8×
Earnings
Earnings dates are not tracked in this release.
Concentration
Single-name equity — no diversification within the position.

Estimated annualized volatility 46% with a maximum drawdown of 47% over the available window.

Investment Thesis (generated summary)

Alnylam Pharmaceuticals Inc (ALNY) screens constructively on the current data, with an opportunity score of 72/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case
  • Strong net margin (54%)
  • Revenue growing 56% y/y
  • Low P/E (8×)
Bearish case
  • Underperforming peers
Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.
Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.
News Sentiment
Bullish 0%Neutral 0%Bearish 0%
No recent news analyzed — sentiment defaults to neutral.
Disclaimer. AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results.
ALNY Stock Intelligence & Analysis · 360head Stockiq